Klinische studies multipel myeloom

Onbehandelde patiënten

MajesTEC-4

Phase 3 Study of Teclistamab in Combination with Lenalidomide versus Lenalidomide Alone in Participants with Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

• Principal investigator: Prof. Dr. Michel Delforge
• More information: NCT05243797
• Internal reference number: S66158

MajesTEC-7

A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy

• Principal investigator: Prof. Dr. Michel Delforge
• More information: NCT05552222
• Internal reference number: S66873

LUMYA (EMN39)

A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients

• Principal investigator: Prof. Dr. Michel Delforge
• More information: NCT06932562
• Internal reference number: S70483

Behandelde patiënten

iMMagine-3 (KT-US-679-0788)

A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma

• Principal investigator: Prof. Dr. Koen Debackere
• More information: NCT06413498
• Internal reference number: S69321

Papilio-1

A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured anti-BCMA CAR T cells (GLPG5301;BCMACP03) in subjects with relapsed/refractory multiple myeloma

• Principal investigator: Prof. Dr. Koen Debackere
• More information: EUCT2022-500782-27-00
• Internal reference number: S69267

M25-275

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor ABBV-453 given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma – Substudy1

• Principal investigator: Prof. Dr. Michel Delforge
• More information: NCT06953960
• Internal reference number: S70478